The clinical validation of the test was initially performed in the study that included 205 archival FFPE breast cancer samples of lymph node-positive (LN+), estrogen receptor-positive (ER+), HER2-negative patients (HER2−), treated with adjuvant anthracycline-based chemotherapy. The gene discussed is ERBB2; the disease is breast cancer.